These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34032593)

  • 1. Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Bar-Or A; Herman A; Stokmaier D
    Neurology; 2021 May; 96(18):870. PubMed ID: 34032593
    [No Abstract]   [Full Text] [Related]  

  • 2. Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Hahn N
    Neurology; 2021 May; 96(18):870. PubMed ID: 34032592
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
    Bar-Or A; Calkwood JC; Chognot C; Evershed J; Fox EJ; Herman A; Manfrini M; McNamara J; Robertson DS; Stokmaier D; Wendt JK; Winthrop KL; Traboulsee A
    Neurology; 2020 Oct; 95(14):e1999-e2008. PubMed ID: 32727835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    Sankari SE; Van Essche C; van Pesch V
    J Neurol; 2021 Nov; 268(11):4376-4378. PubMed ID: 34181076
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocrelizumab: its efficacy and safety in multiple sclerosis.
    Juanatey A; Blanco-Garcia L; Tellez N
    Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.
    Marrodan M; Laviano J; Oneto S; Reino FM; Delorme R; Fornillo F; Férnandez J; Correale J
    Neurol Sci; 2021 Sep; 42(9):3893-3895. PubMed ID: 34075515
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute cerebellitis requiring posterior fossa decompression after COVID-19 vaccination in an ocrelizumab-treated patient with multiple sclerosis.
    Brecl Jakob G; Savšek L; Meglič B
    Neurol Sci; 2022 Jun; 43(6):3509-3511. PubMed ID: 35226212
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.
    Adamec I; Reiner Ž; Pećin I; Šućur N; Godan Hauptman A; Barun B; Gabelić T; Habek M
    Mult Scler Relat Disord; 2020 Oct; 45():102381. PubMed ID: 32653735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab for multiple sclerosis.
    Drug Ther Bull; 2018 Jul; 56(7):80-84. PubMed ID: 30008443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Drug For Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
    [No Abstract]   [Full Text] [Related]  

  • 12. Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report.
    Joubert M; Paris P; Clavelou P; Moisset X
    Rev Neurol (Paris); 2021 Oct; 177(8):1041-1042. PubMed ID: 33618890
    [No Abstract]   [Full Text] [Related]  

  • 13. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of natalizumab.
    Tanaka M
    Mult Scler; 2019 Oct; 25(12):1689-1690. PubMed ID: 30485149
    [No Abstract]   [Full Text] [Related]  

  • 17. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.
    Menge T; Dubey D; Warnke C; Hartung HP; Stüve O
    Expert Rev Neurother; 2016 Oct; 16(10):1131-9. PubMed ID: 27552111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.
    Prockl V; Nickel FT; Utz KS; Fröhlich K; Engelhorn T; Hilz MJ; Lee DH; Linker RA; Huhn K
    J Neurol Sci; 2020 Aug; 415():116973. PubMed ID: 32563101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.
    Popescu V; Beirinckx A; Decallonne B
    Acta Neurol Belg; 2022 Aug; 122(4):1117-1120. PubMed ID: 35589913
    [No Abstract]   [Full Text] [Related]  

  • 20. Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate.
    Filippini G
    Evid Based Med; 2017 Dec; 22(6):215-216. PubMed ID: 29117998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.